These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31248662)

  • 1. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
    Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
    BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
    Mathur VS; Li E; Wesson DE
    Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
    Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
    J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
    Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
    Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
    Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
    J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
    Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
    Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
    Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial.
    BiCARB study group
    BMC Med; 2020 Apr; 18(1):91. PubMed ID: 32268897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veverimer: An Emerging Potential Treatment Option for Managing the Metabolic Acidosis of CKD.
    Adrogué HJ; Madias NE
    Am J Kidney Dis; 2020 Dec; 76(6):861-867. PubMed ID: 32920151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
    Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Potential for Veverimer Drug-Drug Interactions.
    Parsell D; Shao J; Guttendorf R; Mathur V; Li E; Wu YS; Tsao L; Tabakman S; Stasiv Y; Lee A; Biyani K; Klaerner G
    Drug Metab Dispos; 2021 Jul; 49(7):490-500. PubMed ID: 34031138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.
    Witham MD; Band MM; Littleford RC; Avenell A; Soiza RL; McMurdo ME; Sumukadas D; Ogston SA; Lamb EJ; Hampson G; McNamee P;
    Trials; 2015 Aug; 16():326. PubMed ID: 26231610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in management of chronic metabolic acidosis in chronic kidney disease.
    Chen W; Abramowitz MK
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Veverimer in the Treatment of Metabolic Acidosis Caused by Chronic Kidney Disease: A Meta-analysis.
    Liu W; Li L; Zhang X; Dong H; Lu M
    Front Pharmacol; 2021; 12():643128. PubMed ID: 33995050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.